scholarly journals Prognostic value of postoperative high-sensitivity troponin T in patients with different stages of kidney disease undergoing noncardiac surgery

2018 ◽  
Vol 120 (1) ◽  
pp. 84-93 ◽  
Author(s):  
V.G.B. Liem ◽  
S.E. Hoeks ◽  
F. Grüne ◽  
K.H.J.M. Mol ◽  
F.H.I.M. Wesdorp ◽  
...  
Keyword(s):  
Kidney Disease ◽  
Prognostic Value ◽  
Troponin T ◽  
High Sensitivity ◽  
Noncardiac Surgery ◽  
High Sensitivity Troponin ◽  
High Sensitivity Troponin T

Prognostic Value of Combination of High-sensitivity Troponin T and BNP in Outpatients with Chronic Kidney Disease

2012 ◽  
Vol 18 (10) ◽  
pp. S178
Author(s):  
Hiroyuki Naruse ◽  
Junnichi Ishii ◽  
Ryuunosuke Okuyama ◽  
Tousei Hashimoto ◽  
Kousuke Hattori ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Prognostic Value ◽  
Troponin T ◽  
High Sensitivity ◽  
High Sensitivity Troponin ◽  
High Sensitivity Troponin T

scholarly journals Prognostic Value of N-Terminal Pro-Brain Natriuretic Peptide and High-Sensitivity Troponin T Levels in the Natural History of Transthyretin Amyloid Cardiomyopathy and Their Evolution after Tafamidis Treatment

2021 ◽  
Vol 10 (21) ◽  
pp. 4868
Author(s):  
Silvia Oghina ◽  
Constant Josse ◽  
Mélanie Bézard ◽  
Mounira Kharoubi ◽  
Marc-Antoine Delbarre ◽  
...  
Keyword(s):  
Brain Natriuretic Peptide ◽  
Natriuretic Peptide ◽  
Prognostic Value ◽  
Troponin T ◽  
High Sensitivity ◽  
Relative Increase ◽  
High Sensitivity Troponin ◽  
Increased Risk ◽  
Amyloid Cardiomyopathy ◽  
High Sensitivity Troponin T

Background: We assesse the evolution and prognostic value of N-terminal pro-brain natriuretic peptide (NT-proBNP) and high-sensitivity troponin T (cTnT-HS) in transthyretin amyloid cardiomyopathy (ATTR-CA) before and after tafamidis treatment. Methods and Results: 454 ATTR-CA patients without tafamidis (Cohort A) and 248 ATTR-CA with tafamidis (Cohort B) were enrolled. Event-free survival (EFS) events were death, heart transplant, or acute heart failure. In Cohort A, 27% of patients maintained NT-proBNP < 3000 ng/L and 14% cTnT-HS < 50 ng/L at 12 months relative to baseline levels. In Cohort B, the proportions were 49% and 29%, respectively. In Cohort A, among the 333 patients without an increased NT-proBNP > 50% relative to baseline EFS was extended compared to the 121 patients with an increased NT-proBNP > 50% (HR: 0.75 [0.57; 0.98]; p = 0.032). In Cohort A, baseline NT-proBNP > 3000 ng/L and cTnT-HS > 50 ng/L and a relative increase of NT-proBNP > 50% during follow-up were independent prognostic factors of EFS. The slopes of logs NT-proBNP and cTnT-HS increased with time before and stabilized after tafamidis. Conclusion: ATTR-CA patients with increasing NT-proBNP had an increased risk of EFS. Tafamidis stabilize NT-proBNP and cTnT-HS increasing, even if initial NT-proBNP levels were >3000 ng/L. Thus suggesting that all patients, irrespective of baseline NT-proBNP levels, may benefit from tafamidis.

Sign in / Sign up

Export Citation Format

Share Document